We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.53% | 43.58 | 43.68 | 43.27 | 43.58 | 4,048,068 | 01:00:00 |
From May 2019 to May 2024
By Rory Gallivan
LONDON--The European Union has approved GlaxoSmithKline PLC's (GSK.LN) and Genmab A/S's (GEN.KO) leukemia treatment Arzerra to be used in patients unable to use an alternative drug.
The companies said Thursday that the EU has given marketing permission for Arzerra "as first-line treatment for chronic lymphocytic leukemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy."
Jan van de Winkel, chief executive of Genmab said: "This is another important milestone and we look forward to a successful launch under this new indication of the drug in Europe in the coming months."
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
